{"nctId":"NCT00249821","briefTitle":"Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age","startDateStruct":{"date":"2005-02-28","type":"ACTUAL"},"conditions":["Small Gestational Age (SGA)"],"count":22,"armGroups":[{"label":"Saizen® 0.057 mg/kg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Saizen®"]},{"label":"Saizen® 0.035 mg/kg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Saizen®"]}],"interventions":[{"name":"Saizen®","otherNames":["somatropin"]},{"name":"Saizen®","otherNames":["somatropin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nTo be eligible for inclusion / randomization into this study, the subjects must fulfill all of the following criteria (if there is no inclusion phase, the inclusion criteria will be considered as inclusion criteria for randomization):\n\n* Written consent form signed by the parents / legal guardian, and child if possible\n* Subject born SGA and receiving a r-hGH therapy for this pathology\n* Recombinant human growth hormone (r-hGH) started at the maximal chronological age of 7 years for girls and 8 years for boys\n* Treatment with r-hGH started for at least 30 months and less than 36 months at 0.057 mg/kg/day\n* Height gain during the first 2 years of GH treatment \\> 1 SD compared with the initial value\n\nExclusion Criteria:\n\nTo be eligible for inclusion in this study the subjects must not meet any of the following criteria:\n\n* Known hypersensitivity to Somatropin or any of the excipients\n* Active neoplasia (either newly diagnosed or recurrent)\n* Intracranial hypertension\n* Known diabetes mellitus\n* Proliferative or preproliferative diabetic retinopathy\n* Evidence of any progression or recurrence of an underlying intra-cranial space occupying lesion\n* Obesity defined as degree 1 on the corpulence curves\n* Precocious puberty\n* Pubertal status: Tanner breast development stage \\> 2 for girls, and testicular volume \\> 4 milliliter (mL) or testicular length \\> 3 centimeter (cm) and/or testosterone value \\>1 nanomole/liter \\[nmol/L\\] (0.29 gram/mL \\[g/mL\\]) for boys For girls \\> 9 years and Tanner breast development stage 1: uterine size \\> 35 millimeter (mm)\n* Severe chronic concomitant illness such as chronic renal failure, cystic fibrosis\n* Concomitant corticoid treatment or levothyroxine treatment other than substitutive treatment, topical or inhaled treatment\n* Participation to any clinical study within the 30 days preceding study entry","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Height Velocity","description":"Height Velocity (HV) is the change in height since the previous year´s measurement and more precisely: HV = {(h-hp)/(d-dp)} \\* 365.25 \\[centimeter (cm)/year\\] where h is current height in cm, hp is previous height in cm, closest to 1 year previous, d is the current date and dp is the date of measurement of previous height, closest to 1 year previous. Additionally, d and dp have to be within 0.6 years and 1.5 years. HV is the mean height velocity over the interval between d and dp but is displayed as HV at d.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.40","spread":"1.35"},{"groupId":"OG001","value":"4.40","spread":"1.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Height-Standard Deviation Score (H-SDS) at Month 6 and Month 12","description":"Height-Standard Deviation Score (H-SDS) was calculated as height minus mean (age-and sex-matched reference) divided by standard deviation (SD) \\[age and sex-matched reference\\]. Greater H-SDS indicates greater height.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.30","spread":"0.42"},{"groupId":"OG001","value":"-1.50","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.22"},{"groupId":"OG001","value":"0.10","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.30"},{"groupId":"OG001","value":"-0.10","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Height Velocity-Standard Deviation Score (HV-SDS)","description":"Height Velocity-Standard Deviation Score (HV-SDS) was calculated as height velocity minus reference mean height velocity divided by SD of the reference mean height velocity. Greater HV-SDS indicates greater height velocity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"0.44"},{"groupId":"OG001","value":"0.10","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.29"},{"groupId":"OG001","value":"-0.10","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Height at Month 6","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121.10","spread":"7.99"},{"groupId":"OG001","value":"119.20","spread":"5.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":"1.31"},{"groupId":"OG001","value":"2.50","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bone Age at Month 12","description":"Bone age was assessed by a left wrist X-Ray and evaluated by the investigator according to the Greulich and Pyle method.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.50","spread":"0.82"},{"groupId":"OG001","value":"7.00","spread":"1.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"0.79"},{"groupId":"OG001","value":"1.40","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Insulin Like Growth Factor-1 (IGF-1) Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"319.60","spread":"146.27"},{"groupId":"OG001","value":"275.40","spread":"98.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"369.30","spread":"120.13"},{"groupId":"OG001","value":"262.40","spread":"65.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"414.30","spread":"176.70"},{"groupId":"OG001","value":"263.00","spread":"120.70"}]}]}]},{"type":"SECONDARY","title":"Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.40","spread":"0.70"},{"groupId":"OG001","value":"3.40","spread":"0.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":"0.84"},{"groupId":"OG001","value":"3.30","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":"1.02"},{"groupId":"OG001","value":"3.50","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","description":"Adverse Events (AEs): Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs that occur during treatment with the Investigational Medicinal Product (IMP).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":["Asthma","Bronchitis","Ear infection","Insulin-like growth factor increased"]}}}